信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌:个案报道并文献复习  

PD-1 combined with surufatinib for the treatment of metastatic colon cancer with microsatellite stability and BRAF V600E mutation:A case report and review

作　　者：陈润芝 杨东梅 徐慧婷[1] Chen Runzhi;Yang Dongmei;Xu Huiting(Department of Abdominal Oncology,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430079,China)

机构地区：[1]华中科技大学附属湖北省肿瘤医院腹部内科,武汉430079

出　　处：《中华结直肠疾病电子杂志》2023年第5期431-435,共5页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：湖北省自然科学基金青年项目(2021CFB267)。

摘　　要：BRAF基因在转移性结直肠癌中的突变率约12%,其中,90%为BRAF V600E突变。常规治疗有效率低,预后差。现报道1例微卫星稳定型(MSS)BRAF V600E突变的晚期结肠癌患者,一线接受BEV+FOLFOXIRI,三线瑞戈非尼靶向治疗后疾病进展,四线接受信迪利单抗联合索凡替尼治疗后获得部分缓解(PR)。BRAF mutation is found in approximately 12% of metastatic colorectal cancer (mCRC), with 90% mutation caused by V600E mutation, which has limited response to conventional therapies and poor prognosis. Here we present a case of an advanced colon cancer patient with BRAF V600E mutation. After a failed therapy with Bevacizumab and FOLFOXIRI, the disease progressed rapidly in the third-line treatment with Regorafenib. Then the patient was initiated on a regimen of sintilimab blockade and Surufatinib which had achieved partial response (PR).

关 键 词：结肠肿瘤 转移性结直肠癌 BRAF突变 索凡替尼 免疫治疗 

分 类 号：R735.35[医药卫生—肿瘤]